Navigation Links
Manhattan Research Survey Finds That Physicians Overwhelmingly Support Commercially-Funded Continuing Medical Education
Date:1/27/2009

NEW YORK, Jan. 27 /PRNewswire/ -- A study by healthcare market research firm Manhattan Research found that only 9% of U.S. physicians oppose commercial support for continuing medical education (CME) funding. The results of this study are relevant to the ongoing discussion in the medical community about the role of commercial funding of CME.

In an effort to better understand the positions of those who actually use continuing medical education, Manhattan Research surveyed physicians on their opinions with regard to their use and the potential bias of industry-funded programs. The Manhattan Research study reports that only 8% of physicians who participated in CME believe that it is biased. In fact, if commercial support is halted, nearly half of the physicians surveyed would decrease their use of CME.

According to the study, almost all physicians utilize CME programs to maintain and grow their medical knowledge and to keep up-to-date on the latest advances in their specialty with the ultimate goal of improving patient care. Pharmaceutical companies are a funding source for CME programs, which has prompted some critics to question their influence over CME course content. In response, the Accreditation Council for Continuing Medical Education (ACCME), the organization that accredits CME Providers, has augmented its standards and guidelines to ensure the independence of commercially supported CME activities. The American Medical Association's Council on Ethical and Judicial Affairs (CEJA) is also expected to issue a new report on commercially-supported CME later this year.

"While there's been debate around the value of industry-supported CME, as our study reveals, it's important to listen to the voice of the majority of physicians," said Mark Bard, Manhattan Research President. "Rather than pulling the plug on a vital source of CME funding, the primary beneficiaries of CME - physicians and patients - would be best served by continued improvements to course availability, offerings, and content through increased collaboration among medical and academic organizations, the pharmaceutical industry, CME providers, and accreditation bodies."

About the Study

Healthcare market research firm Manhattan Research conducted a survey to gauge physician opinion on commercially-funded CME and the proposed ban. The online study was fielded in the third quarter of 2008 among a nationally representative sample of U.S. physicians, including primary care and specialist audiences.

Manhattan Research Products and Services

Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com, email sales@manhattanresearch.com or call 1.888.680.0800.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Manhattan Research
    Maureen Malloy
    212-255-7799
    mmalloy@manhattanresearch.com

    Decision Resources, Inc.
    Elizabeth Marshall
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Manhattan Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
2. The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of Affordable Luxury Mini Day Spa Concept
3. Eli Manning Leads March for Babies in Manhattan
4. 1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11
5. Manhattan Scientifics Acquires Metallicum, Inc.
6. Stanford researchers find culprit in aging muscles that heal poorly
7. Children of depressed moms do better when dad is involved, SLU researcher finds
8. UCLA researchers identify markers that may predict diabetes in still-healthy people
9. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
10. New research shows how chronic stress worsens neurodegenerative disease course
11. New research explores newborn in-hospital weight loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality ... 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. ... not only to the association, but also to the Health Care Quality and Patient ...
(Date:3/23/2017)... ... March 23, 2017 , ... The founders of Dr. ... as winners of American Dreams & Good Housekeeping Seal Initiative, a nationwide search ... and Good Housekeeping. , Steven Wang, MD ., a renowned dermatologist and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
(Date:3/23/2017)... ... , ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous ... Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures ... Rose‘s new book presents actual events in the life of her family, which validate ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... , March 23, 2017   Casetabs , the ... native mobile app for the iPhone. With this new ... coordination and communication for physician offices, ambulatory surgery centers ... app offers iPhone users even faster, more reliable access ... it even easier to connect care teams so that ...
Breaking Medicine Technology: